Abstract
Seasonal influenza epidemics occur every winter. In Japan, this season begins from late November to early December and ends in April to May. According to the National Epidemiological Surveillance of Infectious Disease, around 15 million people, which is about 10% of the entire Japanese population, is estimated to be infected every season. Elderly people account for about 10% of all reported patients; however, their cases may become severe and lead to complications such as pneumonia or result in death. As a countermeasure against influenza in elderly people, an inactivated tetravalent vaccine has been recommended as part of the national immunization program since 2017 in Japan.
This chapter describes the characteristics of influenza virus, influenza disease burden in elderly people, and influenza vaccine as an influenza countermeasure and its effectiveness.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American Academy of Pediatrics. Influenza. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red Book: 2015 Report of the committee on infectious diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. p. 476–93.
Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455(7212):532–6.
Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20):1945–52.
Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021–5.
National Institute of Infectious Diseases Japan. Influenza in this season (2016/17) in Japan. 2017 (in Japanese). https://www.niid.go.jp/niid/images/idsc/disease/influ/fludoco1617.pdf.
Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369.
Holter JC, Muller F, Bjorang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis. 2015;15:64.
Hirota Y, Kaji M. History of influenza vaccination programs in Japan. Vaccine. 2008;26(50):6451–4.
Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344(12):889–96.
Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1–62.
Nobuhara H, Watanabe Y, Miura Y. Estimation of influenza vaccination coveraged in Japan (in Japanese). Jpn J Public Health. 2014;61(7):354–9.
Greenwood M, Yule GU. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med. 1915;8(Sect Epidemiol State Med):113–94.
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-8):1–40.
Hara M, Sakamoto T, Tanaka K. Effectiveness of influenza vaccination in preventing influenza-like illness among community-dwelling elderly: population-based cohort study in Japan. Vaccine. 2006;24(27–28):5546–51.
Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013;31(50):6030–3.
Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;35(36):4796–800.
Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51.
Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis. 2014;14(12):1228–39.
Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Bethesda, MD: Food and Drug Administration; 2007. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.
European Committee for Proprietary Medial Products. Note for guidance on harmonisation of requirements for influenza vaccine (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medical Products; 1997. http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf.
Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69.
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 influenza season. MMWR Recomm Rep. 2017;66(2):1–20.
Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ. 1993;307(6910):988–90.
Centers for Disease Control and Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)—United States, May–August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071–4.
Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001;357(9261):1008–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hara, M. (2019). Influenza and Influenza Vaccination in Japanese Elderly. In: Washio, M., Kiyohara, C. (eds) Health Issues and Care System for the Elderly. Current Topics in Environmental Health and Preventive Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-13-1762-0_12
Download citation
DOI: https://doi.org/10.1007/978-981-13-1762-0_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1761-3
Online ISBN: 978-981-13-1762-0
eBook Packages: MedicineMedicine (R0)